Exploiting multiple hit-identification strategies to identify novel inhibitors of the anti-infective target DXPS
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Saarbrücken, Universität des Saarlandes, Dissertation, 2022
- Ereignis
-
Veröffentlichung
- (wo)
-
Saarbrücken
- (wer)
-
Saarländische Universitäts- und Landesbibliothek
- (wann)
-
2022
- Urheber
-
Johannsen, Sandra
- Beteiligte Personen und Organisationen
-
Hirsch, Anna K. H.
- DOI
-
10.22028/D291-37477
- URN
-
urn:nbn:de:bsz:291--ds-374775
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:50 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Johannsen, Sandra
- Hirsch, Anna K. H.
- Saarländische Universitäts- und Landesbibliothek
Entstanden
- 2022
Ähnliche Objekte (12)
Altes Target, Neue Hits - Entwicklung von Inhibitoren für die PIM1-Kinase
Predicting and Exploiting the Determinants of Protein/Protein Interactions to Identify Low-Molecular Inhibitors of RUNX1-ETO Tetramerization
Exploiting background knowledge on evolving objects to identify relevant dimensions for classification
Targets and Off-Targets of Kinase Inhibitors in Diabetes
Exploiting the ubiquitin system to identify novel vulnerabilities in B-cell malignancies and lung adenocarcinoma
Targets missed: three case studies exploiting the linked SHARE-RV data
RNAi screen in primary AML cells to identify new therapeutic targets
Target gene regulation by EBV latent transcription factors - exploiting cellular enhancer elements
Pharmacological plasticity - how do you hit a moving target?
Neue Strukturen und Targets für β-Laktamase-Inhibitoren [Beta-Laktamase-Inhibitoren]
Neue Strukturen und Targets für β-Laktamase-Inhibitoren [Beta-Laktamase-Inhibitoren]
In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets
Altes Target, Neue Hits - Entwicklung von Inhibitoren für die PIM1-Kinase
Predicting and Exploiting the Determinants of Protein/Protein Interactions to Identify Low-Molecular Inhibitors of RUNX1-ETO Tetramerization
Exploiting background knowledge on evolving objects to identify relevant dimensions for classification
Targets and Off-Targets of Kinase Inhibitors in Diabetes
Exploiting the ubiquitin system to identify novel vulnerabilities in B-cell malignancies and lung adenocarcinoma
Targets missed: three case studies exploiting the linked SHARE-RV data
RNAi screen in primary AML cells to identify new therapeutic targets
Target gene regulation by EBV latent transcription factors - exploiting cellular enhancer elements
Pharmacological plasticity - how do you hit a moving target?
Neue Strukturen und Targets für β-Laktamase-Inhibitoren [Beta-Laktamase-Inhibitoren]
Neue Strukturen und Targets für β-Laktamase-Inhibitoren [Beta-Laktamase-Inhibitoren]
In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets
Altes Target, Neue Hits - Entwicklung von Inhibitoren für die PIM1-Kinase
Predicting and Exploiting the Determinants of Protein/Protein Interactions to Identify Low-Molecular Inhibitors of RUNX1-ETO Tetramerization
Exploiting background knowledge on evolving objects to identify relevant dimensions for classification
Targets and Off-Targets of Kinase Inhibitors in Diabetes
Exploiting the ubiquitin system to identify novel vulnerabilities in B-cell malignancies and lung adenocarcinoma
Targets missed: three case studies exploiting the linked SHARE-RV data
RNAi screen in primary AML cells to identify new therapeutic targets
Target gene regulation by EBV latent transcription factors - exploiting cellular enhancer elements
Pharmacological plasticity - how do you hit a moving target?
Neue Strukturen und Targets für β-Laktamase-Inhibitoren [Beta-Laktamase-Inhibitoren]
Neue Strukturen und Targets für β-Laktamase-Inhibitoren [Beta-Laktamase-Inhibitoren]